Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Company Overview

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $10.50 to $11.00
• 50-Day Range: $10.36 to $12.15
• 52-Week Range: $0.80 to $14.26
• Volume: 434 shs
• Average Volume: 25,263 shs
• Market Capitalization: $17.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FNCH Stock Analysis - Frequently Asked Questions

How have FNCH shares performed this year?

Finch Therapeutics Group's stock was trading at $3.61 at the beginning of 2024. Since then, FNCH stock has increased by 204.7% and is now trading at $11.00.
View the best growth stocks for 2024 here.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) released its earnings results on Wednesday, November, 10th. The company reported ($6.30) earnings per share for the quarter, topping the consensus estimate of ($12.60) by $6.30. The firm earned $11.34 million during the quarter.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group shares reverse split on the morning of Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Finch Therapeutics Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FNCH
• CUSIP: N/A
• CIK: 1733257
• Web: www.finchtherapeutics.com
• Phone: 617-229-6499
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-74,750,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.14%
• Return on Assets: -26.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $110,000.00
• Price / Sales: 160.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.25 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 1,606,000
• Free Float: 885,000
• Market Cap: $17.67 million
• Optionable: No Data
• Beta: 1.29